Stem Cell Therapy for Diabetes and Related Conditions - A Pipeline Analysis Report

PART 01: Executive summary

PART 02: Scope

• Scope of the report

PART 03: Disease overview

• Introduction

PART 04: Regulatory framework

PART 05: Drug development landscape

• Drugs under development

PART 06: Drug development strategies

• Therapies employed
• RoA
• Therapeutic modalities
• Targets for drug development
• Mechanism of action (MoA)

PART 07: Recruitment strategies

• Geographical coverage
• Recruitment status
• Gender of participants
• Age structure
• Recruitment volume

PART 08: Key companies

• Overview
• Type of players

PART 09: AgeX Therapeutics Inc.

• Overview

PART 10: Anterogen Co. Ltd.

• Overview

PART 11: Caladrius Biosciences Inc.

• Overview

PART 12: Evotec

• Overview

PART 13: Fresenius Medical Care AG & Co. KGaA

• Overview

PART 14: Kadimastem Ltd.

• Overview

PART 15: Mesoblast Ltd.

• Overview

PART 16: NextCell Pharma AB

• Overview

PART 17: Ossium Health

• Overview

PART 18: PanCryos

• Overview

PART 19: ReNeuron Group plc

• Overview

PART 20: RHEACELL GmbH & Co. KG

• Overview

PART 21: Sana Biotechnology

• Overview

PART 22: Seraxis Inc.

• Overview

PART 23: Sernova Corp.

• Overview

PART 24: Sigilon Therapeutics Inc.

• Overview

PART 25: Thomas Advanced Medical LLC

• Overview

PART 26: Tianhe Stem Cell Biotechnologies Inc.

• Overview

PART 27: Vertex Pharmaceuticals Inc.

• Overview

PART 28: ViaCyte Inc.

• Overview

PART 29: XOStem Inc.

• Overview

PART 30: Dormant and Discontinued therapeutic candidates

PART 31: Appendix

• List of abbreviations